Earlier indications signaled that more radium-223 dichloride (Ra-223) for treating metastatic castration-resistant prostate cancer (mCRPC) might be better than the current dosing protocol. However, investigators of a multicenter, international phase II study have concluded that the currently approved dose of Ra-223 appear to be optimal.
The report supporting the current dosing schedule was reported (abstract 5008) at the recent 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study did not show any improvement in survival or symptomatic skeletal event–free survival,” said study coauthor Julie N. Graff, MD, from Oregon Health & Science University School of Medicine, Portland. “I am a little surprised that pain scores did not change with the higher dose or extended treatment.”
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.